Enfuvirtide

Enfuvirtide Overview

Enfuvirtide (formerly known as T-20; chemical formula C108H206N38O39S) is a 36-amino-acid synthetic biomimetic peptide antiretroviral drug. Chemically, it belongs to the class of amino acids, peptides, and proteins within the organic acids superclass. Structurally, its amino acid sequence corresponds directly to the C-terminal heptad repeat 2 (HR2) domain of the transmembrane envelope glycoprotein gp41 of the Human Immunodeficiency Virus Type 1 (HIV-1).

What Is Enfuvirtide and How Does It Work?

Enfuvirtide acts primarily through competitive displacement of the viral gp41 heptad repeat 2 (HR2) domain, halting viral-host membrane fusion.

Its primary chemical, physiological, and viral mechanisms include:

• The Normal HIV-1 Entry Mechanism: Attachment of HIV-1 surface glycoprotein gp120 to the host CD4 receptor and chemokine co-receptors (CCR5 or CXCR4) triggers a conformational change in the transmembrane glycoprotein gp41. This exposes the hydrophobic fusion peptide, which inserts into the host CD4 T-cell membrane.
• Formation of the Six-Helix Bundle: Under uninhibited conditions, the first heptad repeat (HR1) and second heptad repeat (HR2) regions of gp41 fold back on each other to form a stable “six-helix bundle.” This hairpin structure pulls the viral membrane and host CD4 cell membrane into close proximity, enabling membrane fusion and viral capsid entry into the host cytoplasm.
• Competitive Binding to HR1: Enfuvirtide mimics the native HR2 region of gp41. It binds specifically and competitively to the exposed HR1 region on gp41 during the transient intermediate state following CD4 engagement.

Is Enfuvirtide FDA Approved?

Yes, Enfuvirtide (Fuzeon) was approved by the US FDA in March 2003 as a prescription antiretroviral for treatment-experienced patients with HIV-1 infection.

What Is Enfuvirtide Used For?

• Treatment of HIV-1 infection in combination with other antiretroviral agents in treatment-experienced adult and pediatric patients (6 years of age and older) who have ongoing viral replication or multi-drug resistant HIV-1 strains.

Before Receiving Enfuvirtide: Warnings & Precautions

Screen for severe hypersensitivity to enfuvirtide or formulation excipients. Strictly contraindicated if an active severe systemic allergic reaction occurs. Monitor closely for near-universal injection site reactions (painful nodules, induration, cellulitis) and an increased risk of bacterial pneumonia. Use during pregnancy only if clearly needed, and advise mothers with HIV-1 to avoid breastfeeding to prevent viral transmission.

Clinical Safety Warnings

Enfuvirtide carries important clinical safety warnings regarding Injection Site Reactions, Increased Risk of Bacterial Pneumonia, and Hypersensitivity Reactions:

• Injection Site Reactions (ISRs): Occur in nearly 100% of patients. Manifestations include painful nodules, erythema, induration, ecchymosis, and superficial infections at subcutaneous injection sites.
• Risk of Bacterial Pneumonia: Clinical trials demonstrated an increased incidence of bacterial pneumonia in patients receiving Enfuvirtide compared to control groups. Monitor closely for respiratory symptoms.
• Hypersensitivity Reactions: Systemic allergic reactions including rash, fever, chills, hypotension, and elevated liver enzymes occur in less than 1% of patients. Do NOT restart therapy if a severe systemic hypersensitivity reaction occurs.

Who Should Not Receive Enfuvirtide?

• Individuals with a documented severe hypersensitivity (anaphylaxis) to Enfuvirtide or formulation excipients (carbonate, mannitol, sodium hydroxide).

Enfuvirtide, Pregnancy & Lactation

Enfuvirtide is classified as Pregnancy Category B equivalent. Animal reproduction studies showed no evidence of fetal harm or impaired fertility. Controlled human trials in pregnant women are limited; Enfuvirtide should be used during pregnancy only if clearly needed. Breastfeeding is strictly discouraged in mothers with HIV-1 infection to prevent perinatal HIV transmission to the infant.

Tell Your Doctor Before Receiving Enfuvirtide

Inform your infectious disease specialist or physician if you have a history of lung disease, asthma, smoking, low CD4 cell counts, high viral load, or bleeding disorders.

Enfuvirtide Dosage & Administration

Standard adult dosing (ages 16 and older) is 90 mg (1 mL) administered twice daily via subcutaneous injection. Pediatric dosing for ages 6 to 15 is 2 mg/kg subcutaneously twice daily, up to a maximum dose of 90 mg twice daily. Dosage adjustments are not required for renal or hepatic impairment.

Standard Dosing Guidelines

• Adult Dosing (16 Years of Age and Older): Recommended dosage is 90 mg (1 mL) administered twice daily as a subcutaneous injection into the upper arm, anterior thigh, or abdomen.
• Pediatric Dosing (6 to 15 Years of Age): Administered subcutaneously twice daily at a dose of 2 mg/kg, up to a maximum dose of 90 mg (1 mL) twice daily.
• Renal and Hepatic Impairment Dosing: Dosage adjustments are not required for patients with renal impairment (eGFR>35 mL/min) or hepatic dysfunction, as Enfuvirtide undergoes peptide catabolism rather than CYP-mediated metabolism or renal excretion.

How Enfuvirtide Is Administered

1. Reconstitute the 108 mg lyophilized powder vial with 1.1 mL of Sterile Water for Injection to yield a 90 mg/mL injectable solution.
2. Tap the vial gently to mix; allow the vial to stand for up to 45 minutes until the powder dissolves completely into a clear, colorless solution. Do NOT shake or foam.
3. Draw up 1 mL (90 mg) into a dedicated 1-mL subcutaneous syringe.
4. Inject subcutaneously into the abdomen, thigh, or upper arm, rotating injection sites with every dose. Do NOT inject into muscle, veins, moles, scars, bruised areas, or active ISR nodules.

Enfuvirtide Clinical Efficacy & Research

The approval of Enfuvirtide was established in two pivotal Phase 3 randomized, open-label trials (TORO 1 and TORO 2) in treatment-experienced adults with multi-drug resistant HIV-1. Adding Enfuvirtide to an optimized background antiretroviral regimen resulted in significantly greater reductions in plasma HIV-1 RNA levels (mean viral load reduction of −1.52 log10​ copies/mL) and significantly higher CD4 cell count gains (+65 cells/mm3) at 24 and 48 weeks compared to optimized background therapy alone.

Enfuvirtide Side Effects & Safety Profile

Binds to the HR1 region of viral gp41, preventing six-helix bundle formation and halting HIV-1 fusion with host CD4 cell membranes. Common side effects include injection site reactions (pain, induration, erythema in over 98% of patients), fatigue, headache, nausea, and peripheral neuropathy. Serious risks include bacterial pneumonia, severe subcutaneous infections (abscesses, cellulitis), and systemic anaphylaxis.

Common Side Effects

• Localized Reactions: Injection site pain, swelling, induration, skin nodules, erythema, and pruritus (occurring in >98% of patients).
• Systemic: Fatigue, headache, nausea, peripheral neuropathy, and insomnia.

Serious Adverse Events

• Bacterial Pneumonia: Increased risk of community-acquired bacterial pneumonia, requiring prompt anti-infective treatment.
• Severe Hypersensitivity: Anaphylactic shock, severe cutaneous reactions, bronchospasm, and acute hypotension.
• Systemic Infections: Abscesses and cellulitis at subcutaneous injection sites.
• Thrombocytopenia & Bleeding: Transient reductions in platelet counts and localized hematoma formation at injection sites.

Managing Side Effects

Rotate subcutaneous injection sites continuously to minimize severe tissue induration. Instruct patients to maintain sterile injection techniques to prevent bacterial cellulitis.

Enfuvirtide Drug Interactions & What to Avoid

Enfuvirtide is catabolized into constituent amino acids in tissue fluids and does not induce or inhibit Cytochrome P450 enzymes. It exhibits no significant metabolic drug-drug interactions with oral antiretrovirals, boosted protease inhibitors, or rifampicin. Avoid excessive alcohol consumption to support overall immune function and liver health.

Drug-Drug Interactions

• Cytochrome P450 Enzymes: Enfuvirtide is an amino acid peptide catabolized in tissue fluids; it does NOT induce or inhibit Cytochrome P450 enzymes (CYP3A4, CYP2C19, CYP2E1) and shows no significant metabolic drug-drug interactions with oral antiretrovirals (e.g., protease inhibitors, NNRTIs, NRTIs, or integrase inhibitors).
• Ritonavir, Saquinavir, Rifampicin: Pharmacokinetic studies confirm no clinically relevant changes in clearance when co-administered with boosted protease inhibitors or rifampicin.

Food & Alcohol

Parenteral administration is independent of meal timing. Food intake does not alter subcutaneous absorption kinetics. Avoid excessive alcohol consumption to support overall immune function and liver health.

Enfuvirtide Overdose, Emergency & Clearance

Absorbed subcutaneously with peak plasma concentrations in 4 to 8 hours and 92% protein binding, undergoing non-CYP peptide catabolism with an elimination half-life of 3.8 hours. Overdose increases injection site pain and systemic fatigue, managed via supportive care; hemodialysis is ineffective. Store dry powder at 20°C to 25°C; reconstituted solutions must be refrigerated at 2°C to 8°C and used within 24 hours.

Elimination Kinetics & Clearance

Following subcutaneous administration of a 90 mg dose, peak plasma concentrations (Cmax​) occur within 4 to 8 hours, with absolute bioavailability of approximately 84%. It binds heavily to human plasma proteins (approx. 92%), primarily albumin. It does not undergo hepatic CYP metabolism; instead, it undergoes catabolic hydrolysis into constituent amino acids in vascular and tissue fluids. The elimination half-life (t1/2​) is approximately 3.8 hours. Overdose leads to exaggerated injection site discomfort and systemic fatigue. Treatment is supportive; hemodialysis does not remove Enfuvirtide due to high plasma protein binding.

Storage & Handling

Store dry powder vials at controlled room temperature between 20°C and 25°C (68°F to 77°F). Following reconstitution with Sterile Water for Injection, the solution may be stored under refrigeration (2°C to 8°C) and must be used within 24 hours. Do not freeze. Keep strictly out of reach of children.

Enfuvirtide Patient Management & Safety Protocols

Instruct patients on sterile reconstitution, the required 45-minute stand time, and gentle handling without shaking to prevent foaming. Inspect injection sites regularly for signs of bacterial cellulitis or abscesses, and monitor CD4 T-cell counts, viral load, and respiratory symptoms for bacterial pneumonia.

Clinical Monitoring Checklist

• Monitor plasma HIV-1 RNA viral load and CD4 T-cell counts every 3 to 4 months.
• Inspect subcutaneous injection sites regularly for signs of bacterial cellulitis or abscess formation.
• Assess for signs and symptoms of bacterial pneumonia (fever, cough, shortness of breath).
• Instruct patient on sterile reconstitution, 45-minute stand time, and proper subcutaneous injection techniques.

Key Do’s and Don’ts

• Do reconstitute with Sterile Water for Injection and allow 45 minutes for complete dissolution without shaking.
• Do rotate injection sites between the abdomen, thigh, and upper arm with every dose.
• Do report signs of infection at injection sites or respiratory symptoms immediately.
• Do not inject into muscle, veins, scars, or existing injection nodules.
• Do not shake reconstituted vials, as shaking creates foam that alters dosage delivery.
• Do not discontinue therapy without consulting your HIV specialist.

Frequently Asked Questions

References

• DrugBank Database – Enfuvirtide Profile (DB00109)
• Official FDA Prescribing Information – Fuzeon (Enfuvirtide Injection)
• European Medicines Agency (EMA) – Fuzeon Assessment Report and Summary of Product Characteristics
• New England Journal of Medicine – TORO 1 and TORO 2 Phase 3 Trials of Enfuvirtide in Treatment-Experienced HIV-1 Patients

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.